CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. (17th January 2020)

• Record Type: Journal Article
• Authors: Zhang, Qingyang; Ping, Jieming; Huang, Zirui; Zhang, Xiaoli; Zhou, Jingyi; Wang, Gangyang; Liu, Shaoyang; Ma, Jianjun
• Other Names: Sato Takami Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2020(2020)
• Publication Date: 2020-01-17
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2020/1924379
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : Chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. Like other technologies, CAR-T cell therapy has undergone a long development process, and persistent explorations of the actions of the intracellular signaling domain and make several improvements have led to the superior efficacy when anti-CD19 CAR-T cell treatments in B cell cancers. At present, CAR-T cell therapy is developing rapidly, and many clinical trials have been established on a global scale, which has great commercial potential. This review mainly describes the toxicity of CAR-T cell therapy and the challenges of CAR-T cells in the treatment of solid tumors, and looks forward to future development and opportunities for immunotherapy and reviews major breakthroughs in CAR-T cell therapy.